STEPHEN H. ROSENOFF, M.D.; ROBERT C. YOUNG, M.D., F.A.C.P.; TOM ANDERSON, M.D.; CHARLES BAGLEY, M.D.; BRUCE CHABNER, M.D., F.A.C.P.; PHILIP S. SCHEIN, M.D., F.A.C.P.; SUSAN HUBBARD, R.N.; VINCENT T. DeVITA, M.D., F.A.C.P.
Peritoneoscopy was done within 1 month of exploratory laparotomy in 30 consecutive patients, with ovarian carcinoma as part of their pretreatment evaluation. Six of the 7 patients who were thought to have ovarian carcinoma localized to the pelvis (stages I and II) were found to have advanced disease (stage III) at peritoneoscopy and thus required a change in therapy. Metastatic diaphragmatic involvement in ovarian carcinoma is common and was found in 77% of all patients studied. The routine shielding of the liver area ordinarily used with total abdominal radiotherapy would select these patients for therapeutic failure. Peritoneoscopy supplied reevaluate findings in 2 of the 7 patients having normal physical, roentgenologic, and laboratory examinations, as well as in 93% of all patients studied. "Second look" peritoneoscopy precluded the need for laparotomy in 5 of 13 patients achieving an apparent clinical remission.
STEPHEN H. ROSENOFF, ROBERT C. YOUNG, TOM ANDERSON, CHARLES BAGLEY, BRUCE CHABNER, PHILIP S. SCHEIN, et al. Peritoneoscopy: A Valuable Staging Tool in Ovarian Carcinoma. Ann Intern Med. 1975;83:37–41. doi: 10.7326/0003-4819-83-1-37
Download citation file:
Published: Ann Intern Med. 1975;83(1):37-41.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use